SCIENCE

Netherlands AI system surpasses doctors in mesothelioma evaluation

▪

Read, Watch or Listen

Researchers at the Netherlands Cancer Institute have developed an artificial intelligence model that more accurately assesses pleural mesothelioma treatment response than human physicians and the current international RECIST criteria. Trained on more than 11,000 CT scans from 2,000 patients across 121 hospitals, the model analyzes complex imaging features to guide decisions on continuing, modifying, or stopping therapy. The peer-reviewed findings, published in The Lancet Oncology on June 18, 2026, represent the first global demonstration of AI outperforming specialists in this niche. Clinicians are beginning to integrate the tool into diagnostic workflows, with researchers stressing it is intended to support, not replace, medical judgment.

Prepared by Olivia Bennett and reviewed by editorial team.

Timeline of Events

2018 Researchers begin assembling multi-hospital CT dataset
2020 Initial AI model architecture designed and tested
2022 Expanded training includes 11,000 CT scans
Early 2025 Model benchmarked against RECIST criteria
Late 2025 Multicenter validation confirms superior accuracy
June 18, 2026 Study published in The Lancet Oncology
June 2026 Clinicians start integrating model into workflows
Today Researchers emphasize AI supports clinical judgment

News Intelligence

This AI tool could mean more accurate treatment for mesothelioma, a rare cancer often linked to asbestos exposure. If you or a loved one are dealing with this disease, it could guide doctors to make better decisions about therapy.